Demographics, genotypes, and disease modifying therapy for IC user population
| IC population characteristics . | IC users, n = 51 . |
|---|---|
| Age, median (range), y | 37 (20-64) |
| Sex, count (%) | |
| Female | 34 (67) |
| Male | 17 (33) |
| Genotype, count (%) | |
| SS | 32 (61) |
| SC | 12 (24) |
| Sβ0 thalassemia | 2 (4) |
| Sβ+ thalassemia | 5 (10) |
| Disease modifying therapy, count (%) | |
| Hydroxyurea | 31 (61) |
| Red cell exchange | 18 (35) |
| IC population characteristics . | IC users, n = 51 . |
|---|---|
| Age, median (range), y | 37 (20-64) |
| Sex, count (%) | |
| Female | 34 (67) |
| Male | 17 (33) |
| Genotype, count (%) | |
| SS | 32 (61) |
| SC | 12 (24) |
| Sβ0 thalassemia | 2 (4) |
| Sβ+ thalassemia | 5 (10) |
| Disease modifying therapy, count (%) | |
| Hydroxyurea | 31 (61) |
| Red cell exchange | 18 (35) |
SC, sickle cell-hemoglobin C disease; SS, sickle cell-hemoglobin S disease.